Navigation Links
In the lab and clinic, VCU Massey develops a new therapy for blood cancers
Date:6/2/2011

Richmond, Va. (June 2, 2011) Clinical researchers at VCU Massey Cancer Center have successfully completed a Phase I clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers, paving the way for a Phase II clinical trial to test the safety and effectiveness of the new therapy.

Reported in the journal Clinical Cancer Research, the study determined the maximum tolerated dose with acceptable side effects for this novel drug combination. The trial represented the first time a proteasome inhibitor such as Bortezomib was combined with a cell cycle inhibitor such as Alvocidib to treat patients with cancer.

Proteasome inhibitors work by blocking the action of proteasomes, which are large protein complexes that help destroy proteins that are no longer needed by the cell. Cell cycle inhibitors disrupt the sequence of events that allow cells to undergo cell division and duplication. They also have the ability to block gene transcription.

The trial included 16 patients who had either indolent (non-aggressive) non-Hodgkin's lymphoma, mantle cell lymphoma or multiple myeloma. After they received the treatments over a 21-day cycle, there were two complete responses, meaning that all detectable traces of the cancer were gone, and five partial responses.

"Therapeutic responses tend to be rare in Phase I trials, but 44 percent of our patient sample responded to the therapy. Interestingly, some patients who previously had no response to Bortezomib, or progressed after Bortezomib therapy, responded to the combination," says Beata Holkova, M.D., a hematologist-oncologist at VCU Massey and co-investigator on this clinical trial. "Because of the small patient sample size, we can't draw definitive conclusions about the effectiveness of the therapy, but we were quite encouraged by the results."

The patients received Bortezomib intravenously on days 1, 4, 8 and 11 and Alvocidib on days 1 and 8. Bortezomib's therapeutic dose alone was not tested because it has already been established and approved to treat certain blood cancers. However, for Alvocidib, the researchers escalated the dose until the maximum tolerated dose was identified. The same researchers are also currently completing a second Phase I clinical trial testing a different delivery schedule of Alvocidib. Although not yet completed, the initial results of this trial appear comparable to the present study.

"This is one of the first trials of its type in which two targeted agents which interfere with two very different biological processes are being combined to treat patients with blood cancers," says co-investigator Steven Grant, M.D., associate director for translational research, co-program leader of Developmental Therapeutics and professor of internal medicine at VCU Massey.

The rationale for this study was developed in Grant's laboratory when synergistic interactions between proteasome and cell cycle inhibitors in malignant blood cancer cells were discovered by Yun Dai, M.D., Ph.D., associate professor of internal medicine at VCU Massey. This laboratory research established the basis for a V Foundation Translational Research Award, which with additional funding from the National Institutes of Health provided the resources necessary to translate the laboratory findings into clinical trials.

Moving forward, the researchers are working with the NCI to develop a Phase II clinical trial to test the effectiveness of this drug therapy. The trial will be conducted in collaboration with multiple institutions to compare the effectiveness of fixed doses of the drug combination in a larger patient population.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Kreativ Dental Clinic, Offering Dental Implant and Dental Services Abroad, Launches 3D Virtual Tours Online
2. VCU Massey research finds new link between inflammation and cancer
3. Key leukemia defense mechanism discovered by VCU Massey Cancer Center
4. VCU Massey Cancer Center awarded $2.4 million grant from Virginia Tobacco Commission
5. Novel therapy for metastatic kidney cancer developed at VCU Massey Cancer Center
6. VCU Massey first to combine targeted agents to kill multiple myeloma cells
7. VCU Massey Cancer Center finds new biomarker that predicts breast cancer relapse
8. Personal Best Develops Workplace Weight Loss Program
9. M. D. Anderson develops tool to measure severity of chronic graft-vs.-host disease symptoms
10. UD team develops new method for producing proteins critical to medical research
11. UMass Memorial health care develops fully integrated EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2017)... ... September 23, 2017 , ... Throughout the United States and the world, ... day, physicians, nurses and other providers work to give the best care possible to ... , But U.S. Senators today are threatening to tie our hands in carrying out ...
(Date:9/24/2017)... , ... September 24, 2017 , ... “Star of Bethlehem ... of Bethlehem Study” is the creation of published author, Duane Engdahl, an investigator who ... by Christian Faith Publishing, Duane Engdahl’s new book is a thought-provoking essay an event ...
(Date:9/22/2017)... Lea, MN (PRWEB) , ... September 22, 2017 , ... ... video) at its rally to interview citizens on why they are rallying against Mayo ... and commitment to this effort against Dr. Noseworthy’s (CEO) decision to close the Albert ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... financial setbacks, a senior finds a new lease on life with assistance from ... of people resolve their problem with unsecured debt. The senior is one of ...
(Date:9/22/2017)... ... 2017 , ... “Cursed with a Curse: The Truth about ... freedom experienced when breaking free from this misconception. “Cursed with a Curse: The ... Published by Christian Faith Publishing, Lysa M. Harrison’s new book is a powerful ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... -- ... Washington DC ... 12 th – Monday, September 18 th .The Brain Tumor Foundation ... scans to the public.Where:  BTF,s Mobile MRI Unit ... Street NW, Washington, D.C.What:BTF brings its nationwide initiative, the Road to Early ...
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company ... Novartis Pharma AG to distribute NuvoAir,s spirometry technology to physicians ... spirometry platform and Novartis, commitment to address the unmet medical ... ... "We ...
Breaking Medicine Technology: